Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Feagan, Brian G, Sandborn, William J, D'Haens, Geert, Panés, Julián, Kaser, Arthur, Ferrante, Marc, Louis, Edouard, Franchimont, Denis, Dewit, Olivier, Seidler, Ursula, Kim, Kyung-Jo, Neurath, Markus F, Schreiber, Stefan, Scholl, Paul, Pamulapati, Chandrasena, Lalovic, Bojan, Visvanathan, Sudha, Padula, Steven J, Herichova, Ivona, Soaita, Adina, Hall, David B and Böcher, Wulf O (2017) Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study The Lancet, 389 (10080). pp. 1699-1709. DOI 10.1016/S0140-6736(17)30570-6.

Full text not available from this repository.

Supplementary data:

Document Type: Article
Research affiliation: OceanRep > The Future Ocean - Cluster of Excellence
Kiel University
Refereed: Yes
DOI etc.: 10.1016/S0140-6736(17)30570-6
ISSN: 01406736
Date Deposited: 21 Dec 2017 11:57
Last Modified: 08 Jan 2018 10:42
URI: http://eprints.uni-kiel.de/id/eprint/41081

Actions (login required)

View Item View Item